319 related articles for article (PubMed ID: 36930430)
1. Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review.
Panaccione R; Lee WJ; Clark R; Kligys K; Campden RI; Grieve S; Raine T
Adv Ther; 2023 May; 40(5):2051-2081. PubMed ID: 36930430
[TBL] [Abstract][Full Text] [Related]
2. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
[TBL] [Abstract][Full Text] [Related]
3. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.
Ylisaukko-Oja T; Puttonen M; Jokelainen J; Koivusalo M; Tamminen K; Torvinen S; Voutilainen M
Scand J Gastroenterol; 2022 Apr; 57(4):415-423. PubMed ID: 34927504
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
Aliment Pharmacol Ther; 2024 Jun; 59(11):1312-1334. PubMed ID: 38651771
[TBL] [Abstract][Full Text] [Related]
5. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Ko Y; Paramsothy S; Yau Y; Leong RW
Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
[TBL] [Abstract][Full Text] [Related]
6. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
7. Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.
Ehrenberg R; Griffith J; Theigs C; McDonald B
J Manag Care Spec Pharm; 2020 Jun; 26(6):758-765. PubMed ID: 32191593
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
[No Abstract] [Full Text] [Related]
10. Treatment and biologic maintenance-dosing patterns among pediatric patients with ulcerative colitis or Crohn's disease.
Hunter T; Komocsar WJ; Colletti RB; Liu C; Benkov KJ; Dotson JL; Steiner SJ; Zhang N; Crandall W;
Curr Med Res Opin; 2023 Jan; 39(1):63-69. PubMed ID: 36263735
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
12. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
[No Abstract] [Full Text] [Related]
13. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
[TBL] [Abstract][Full Text] [Related]
16. Differences in the need for adalimumab dose optimization between Crohn's disease and ulcerative colitis.
Olivares D; Alba C; Pérez I; Roales V; Rey E; Taxonera C
Rev Esp Enferm Dig; 2019 Nov; 111(11):846-851. PubMed ID: 31566410
[TBL] [Abstract][Full Text] [Related]
17. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.
Long MD; Cohen RD; Smith TW; DiBonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Dig Dis; 2022; 40(5):553-564. PubMed ID: 34879378
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
20. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.
Yang H; Li B; Guo Q; Tang J; Peng B; Ding N; Li M; Yang Q; Huang Z; Diao N; Zhu X; Deng J; Guo H; Hu P; Chao K; Gao X
Aliment Pharmacol Ther; 2022 Apr; 55(7):764-777. PubMed ID: 35141914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]